MTOR and lymphangioleiomyomatosis: Our study demonstrates that this was the only relevant side effect of the treatment, as reported in other cohorts of patients affected by other pathologies (tuberous sclerosis complex, lymphangioleiomyomatosis, organ transplantation, and cancer), who were treated with mTOR inhibitors.65 This issue should be considered in cases in which other sirolimus-based clinical interventions have been proposed.